Nincaluicolflastine

Nincaluicolflastine Brand names, Nincaluicolflastine Analogs

Nincaluicolflastine Brand Names Mixture

No information avaliable

Nincaluicolflastine Chemical_Formula

C₄₆H₅₈N₄O₉

Nincaluicolflastine RX_link

http://www.rxlist.com/cgi/generic3/vinblastine.htm

Nincaluicolflastine fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=29

Nincaluicolflastine msds (material safety sheet)

Nincaluicolflastine MSDS

Nincaluicolflastine Synthesis Reference

No information avaliable

Nincaluicolflastine Molecular Weight

810.974 g/mol

Nincaluicolflastine Melting Point

267 ^oC

Nincaluicolflastine H₂O Solubility

Negligible

Nincaluicolflastine State

Solid

Nincaluicolflastine LogP

5.587

Nincaluicolflastine Dosage Forms

Liquid; Powder for solution; Solution

Nincaluicolflastine Indication

For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.

Nincaluicolflastine Pharmacology

Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.

Nincaluicolflastine Absorption